Contribution: Industrial Research Assistance Program – Contributions to Firms
Eupraxia Pharmaceuticals Inc.
$255,400.00
Novel Antibiotic Formulation for Prophylaxis of Post-Surgical Infections
FY 2018-19 · 2018-04-01
Summary
An antibiotic film product will be developed that exhibits sustained-release delivery of high local concentrations of antibiotic at surgical sites for extended duration with limited systemic exposures and effective in experimental models of post-operative infection.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Victoria|Victoria, British Columbia, Canada
Recipient Type
For-profit organization
Business Number
818717308
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-04-01 | 2018-19 | $225,000.00 |
| 1 | 2018-04-01 | 2018-19 | $255,400.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The total amended value is 30,400 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La valeur totale des modifications est de 30 400 dollars.
Agreement End Date
2019-09-30
Agreement Number
905903
Agreement Start Date
2018-04-01
Agreement Title
Novel Antibiotic Formulation for Prophylaxis of Post-Surgical Infections
Agreement Title (French)
Nouvelle formulation d'antibiotique pour la prophylaxie des infections après une intervention chirurgicale
Agreement Type
Contribution
Agreement Value
$255,400.00
Amendment Date
2019-01-11
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
An antibiotic film product will be developed that exhibits sustained-release delivery of high local concentrations of antibiotic at surgical sites for extended duration with limited systemic exposures and effective in experimental models of post-operative infection.
Description (French)
Un produit de film antibiotique sera développé, qui offre de hautes concentrations locales d’antibiotiques à libération soutenue à des sites de chirurgie pour une durée prolongée avec une exposition systémique limitée, et efficace dans des modèles expérimentaux d’infections après une intervention chirurgicale.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Victoria
Federal Riding (French)
Victoria
Federal Riding Number
59041
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
818717308
Recipient City
Victoria|Victoria
Recipient Country
CA
Recipient Legal Name
Eupraxia Pharmaceuticals Inc.
Recipient Postal Code
V8R 5J2
Recipient Province or Territory
BC
Recipient Type
F
Reference Number
172-2018-2019-Q1-905903
